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Phuc Van PhamAbstract
In recent years, both stem cell research and the clinical
application of these promising cells have increased
rapidly. About 1000 clinical trials using stem cells have
to date been performed globally. More importantly,
more than 10 stem cell-based products have been
approved in some countries. With the rapid growth of
stem cell applications, some countries have used clinical
trials as a tool to diminish the rate of clinical stem cell
applications. However, the point at which stem cell
clinical trials are essential remains unclear. This
commentary discusses when stem cell clinical trials are
essential for stem cell transplantation therapies.
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Stem cell transplantationcells. There are two types of stem cell therapy: autolo-Clinical trials
Clinical trials are studies aimed at evaluating whether a
proposed new therapy or drug is safe and effective. New
drugs are compelled to undergo clinical trials. Clinical
trials are commonly divided into four phases (phase I, II,
III, and IV). However, the product is eligible for regulatory
approval after just three successful phases.Stem cells, drugs, and stem cells as drugs
Stem cells are living cells that exist in the human body.
Human growth and development originates from a sin-
gle totipotent stem cell, the zygote. This stem cell prolif-
erates continuously via two mechanisms, symmetric and
asymmetric division [1, 2]. During asymmetric division
in adults, stem cells ensure maintenance of important
roles, in particular homeostasis. Pluripotent stem cells
exist in the early stage of embryo development as the
blastocyst. Almost all adult stem cells exhibit multipo-
tent differentiation potential into a number of cell types.Correspondence: pvphuc@hcmuns.edu.vn
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specific stem cells, with tissues rich in stem cells includ-
ing bone marrow, adipose tissue, and muscle tissue, to
name a few. Traditional drugs are categorized as any
substance other than food used to cause a physiological
change in the body. More commonly, drugs are new
compounds, chemicals, or molecules that are synthe-
sized or extracted from natural materials. However, the
use of stem cells as drugs requires a new definition and
approach. Stem cells as drugs or stem cell drugs are
products containing live stem cells that are used as
drugs.Stem cell therapy, personalized medicine, and
stem cell drugs
Stem cell therapies are treatment procedures using stem
gous and allogeneic stem cell therapies. For autologous
stem cell therapy, or so-called personalized medicine,
the two subgroups include nonexpanded and expanded
autologous stem cell transplantation.
Allogenic stem cell therapy includes stem cell drugs
and expanded or nonexpanded allogenic stem cell ther-
apies. The main difference between stem cell drugs and
other approaches is that stem cell drugs are used to treat
a large population of patients using the same source of
stem cells.When should stem cell clinical trials not be
performed?
As already explained, there are many different ap-
proaches for stem cell therapies. The objectives of clin-
ical trials are drug safety and effectiveness evaluation. In
personalized medicine, the stem cells are obtained from
the patients themselves; therefore the risk of rejection is
negligible. This makes the stem cells safe and nontoxic.
Nonexpanded autologous stem cell therapy is the only
process whereby stem cells are moved from one tissue
to another within the same patient. The key difference
between this approach and the use of new drugs, whichs distributed under the terms of the Creative Commons Attribution 4.0
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Consequently, the main outcome in a clinical trial for
nonexpanded autologous stem cell transplantation is to
investigate treatment efficacy rather than safety of the
stem cells.
A key question is, if a procedure using nonexpanded
autologous stem cell transplantation is successful in one
country, whether it is essential to repeat the clinical trial
in countries aside from the original country? In my
opinion, repeating the clinical trial across different coun-
tries should not be requisite. At present, there are no
findings that can be recorded from these clinical trials.
Why we should not have to repeat clinical trials
Autologous stem cells are very safe. To date, there are
no publications which present stem cells as harmful. In
fact, in a systematic review by Benoit et al. [3], autolo-
gous cell therapy in critical limb ischemia was found to
be 100 % safe in treated patients. Meta-analysis of au-
tologous stem cell transplantation for the treatment of
limb ischemia similarly showed a 100 % safety success
rate [4]. Meta-analysis of autologous stem cell trans-
plantation for the treatment of patients with type 1 and
type 2 diabetes mellitus has also shown a 100 % safety
rate [5, 6]. Furthermore, autologous stem cell therapy
for end-stage liver cirrhosis [7], osteoarthritis [8], and
limbal stem cell deficiency [9] is reported to be 100 %
safe. Subsequent clinical trials using autologous stem cell
transplantation will therefore also determine that this
cell source is 100 % safe.
With respect to autologous patients, some countries
usually apply to repeat clinical trials for new drugs and
for imported approved drugs. Indeed, they need to check
the pharmacology of the drugs within the local patient
population. However, for autologous stem cell therapy,
the “drug” is from the patients themselves. Although the
quality of the stem cell drug may differ between patients,
the pharmacological effects may also differ in different
patients. We therefore cannot control the quality of
autologous stem cell products, meaning that efficacy
may also differ between patients.
When should we perform clinical trials?
Stem cell clinical trials should be carried out in the
following highlighted cases:
(1)A clinical trial can be essential for stem cell drugs.
The quality of the stem cell drug must be
maintained, controlled, and stable. The stem cell
drug will be used in many different patients (a
population); with each patient, the eliciting response
differs using the same drug. The clinical trial should
therefore be carried out to identify new findings for
safety or efficacy in a certain population. Similarly,some clinical trials also can be repeated if there is
any modification that can directly affect stem cell
quality.
(2)Clinical trials may be essential when using allogenic
stem cell transplantation. However, stem cell quality
can differ between donors. The findings from one
donor patient cannot therefore always be applied to
the recipient patient population.
(3)Clinical trials should be carried out using both
autologous and allogeneic expanded stem cell
therapies. However, we need to understand that the
main objective of the clinical trial is for evaluation of
the culture protocol and not the stem cells; for
example, whether ex-vivo culture protocols affect
the stem cell genome stability.
Conclusions
Clinical trials are performed to test the safety and effi-
cacy for a proposed new therapy or drug. However, be-
cause they are different from the traditional definition of
a drug, in some cases stem cells are drugs but in other
cases they represent treatment processes similar to au-
tologous skin grafts. It is therefore nonessential to repeat
clinical trials for nonexpanded autologous stem cell ther-
apies. In fact, there are no new findings regarding autolo-
gous stem cell safety or efficacy following clinical trial
repeats. Clinical trials should be carried out only in some
stem cell drugs, or in cases that could cause changes in
the phenotype or genotype of the stem cells.
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